Peptide News Digest

#Mace

2 stories

Clinical Trials · View digest

Retatrutide Arrhythmia and MACE Safety Signal at ADA 2026: 7 of 403 Arrhythmias and 3 MACE on Drug Versus None on Placebo

STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.

Research · View digest

Anglia Ruskin Meta-Analysis (May 20, Cardiovascular Diabetology - Endocrinology Reports): 90,000+ Patient Review Confirms Long-Term GLP-1 Cardiovascular Protection Across MACE, Heart Failure, Premature Death

Researchers at Anglia Ruskin University published a systematic review and meta-analysis in Cardiovascular Diabetology - Endocrinology Reports on May 20 covering long-term cardiovascular outcomes for glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. The review aggregated data from more than 90,000 participants across large international clinical trials. The headline finding: GLP-1 receptor agonists significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term in patients with established cardiovascular disease and high cardiovascular risk. The review extends the SELECT 20% MACE-reduction signal to the broader high-risk-CV population and joins the established cardiovascular-outcomes evidence base alongside the LEADER (liraglutide), SUSTAIN-6 (semaglutide), and STEP-HFpEF (semaglutide in heart failure) trial readouts. The Anglia Ruskin synthesis is the broadest evidence aggregation to date — directly relevant to the Medicare GLP-1 Bridge that begins July 1, 2026.